Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
66
TGRP Quote, Financials, Valuation and Earnings
Last price:
$0.0500
Seasonality move
:
16.62%
Day range:
$0.0498 - $0.0498
52-week range:
$0.0140 - $0.0900
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.04x
P/B ratio:
188.37x
Volume:
100
Avg. volume:
7.1K
1-year change:
105.79%
Market cap:
$8.7M
Revenue:
$3.8M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGRP
TRON Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -7.04% | -11.5% | $3.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGRP
TRON Pharmaceuticals, Inc.
|
$0.0498 | -- | $8.7M | -- | $0.00 | 0% | 2.04x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$6.45 | $42.50 | $19.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.75 | $27.7M | -- | $0.00 | 0% | 22.36x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.73 | $11.00 | $139.1M | 24.89x | $0.00 | 0% | 2.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGRP
TRON Pharmaceuticals, Inc.
|
-- | -0.049 | -- | -- |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGRP
TRON Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
TRON Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns TGRP or AIM?
AIM ImmunoTech has a net margin of -- compared to TRON Pharmaceuticals, Inc.'s net margin of -10571.43%. TRON Pharmaceuticals, Inc.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital TGRPTRON Pharmaceuticals, Inc.-- -- -- AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About TGRP or AIM?
TRON Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than TRON Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than TRON Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGRPTRON Pharmaceuticals, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is TGRP or AIM More Risky?
TRON Pharmaceuticals, Inc. has a beta of -2.227, which suggesting that the stock is 322.702% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock TGRP or AIM?
TRON Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TRON Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGRP or AIM?
TRON Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. TRON Pharmaceuticals, Inc.'s net income of -- is lower than AIM ImmunoTech's net income of -$3.7M. Notably, TRON Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TRON Pharmaceuticals, Inc. is 2.04x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGRPTRON Pharmaceuticals, Inc.2.04x -- -- -- AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns TGRP or CVM?
CEL-SCI Corp. has a net margin of -- compared to TRON Pharmaceuticals, Inc.'s net margin of --. TRON Pharmaceuticals, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital TGRPTRON Pharmaceuticals, Inc.-- -- -- CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About TGRP or CVM?
TRON Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than TRON Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than TRON Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGRPTRON Pharmaceuticals, Inc.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is TGRP or CVM More Risky?
TRON Pharmaceuticals, Inc. has a beta of -2.227, which suggesting that the stock is 322.702% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock TGRP or CVM?
TRON Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TRON Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGRP or CVM?
TRON Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. TRON Pharmaceuticals, Inc.'s net income of -- is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, TRON Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TRON Pharmaceuticals, Inc. is 2.04x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGRPTRON Pharmaceuticals, Inc.2.04x -- -- -- CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns TGRP or IGC?
IGC Pharma, Inc. has a net margin of -- compared to TRON Pharmaceuticals, Inc.'s net margin of -953.4%. TRON Pharmaceuticals, Inc.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital TGRPTRON Pharmaceuticals, Inc.-- -- -- IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About TGRP or IGC?
TRON Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than TRON Pharmaceuticals, Inc., analysts believe IGC Pharma, Inc. is more attractive than TRON Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGRPTRON Pharmaceuticals, Inc.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is TGRP or IGC More Risky?
TRON Pharmaceuticals, Inc. has a beta of -2.227, which suggesting that the stock is 322.702% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock TGRP or IGC?
TRON Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TRON Pharmaceuticals, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGRP or IGC?
TRON Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. TRON Pharmaceuticals, Inc.'s net income of -- is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, TRON Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TRON Pharmaceuticals, Inc. is 2.04x versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGRPTRON Pharmaceuticals, Inc.2.04x -- -- -- IGCIGC Pharma, Inc.22.36x -- $191K -$1.8M
-
Which has Higher Returns TGRP or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to TRON Pharmaceuticals, Inc.'s net margin of -255.85%. TRON Pharmaceuticals, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TGRPTRON Pharmaceuticals, Inc.-- -- -- NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TGRP or NBY?
TRON Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than TRON Pharmaceuticals, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than TRON Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGRPTRON Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TGRP or NBY More Risky?
TRON Pharmaceuticals, Inc. has a beta of -2.227, which suggesting that the stock is 322.702% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TGRP or NBY?
TRON Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. TRON Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGRP or NBY?
TRON Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. TRON Pharmaceuticals, Inc.'s net income of -- is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, TRON Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TRON Pharmaceuticals, Inc. is 2.04x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGRPTRON Pharmaceuticals, Inc.2.04x -- -- -- NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns TGRP or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to TRON Pharmaceuticals, Inc.'s net margin of 13.19%. TRON Pharmaceuticals, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital TGRPTRON Pharmaceuticals, Inc.-- -- -- PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About TGRP or PLX?
TRON Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than TRON Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than TRON Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGRPTRON Pharmaceuticals, Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is TGRP or PLX More Risky?
TRON Pharmaceuticals, Inc. has a beta of -2.227, which suggesting that the stock is 322.702% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock TGRP or PLX?
TRON Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TRON Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGRP or PLX?
TRON Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. TRON Pharmaceuticals, Inc.'s net income of -- is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, TRON Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TRON Pharmaceuticals, Inc. is 2.04x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGRPTRON Pharmaceuticals, Inc.2.04x -- -- -- PLXProtalix Biotherapeutics, Inc.2.20x 24.89x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 33.49% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 42.66% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.18% over the past day.
